Medical Condition News

RSS

Impax confirms challenge of patent relating to RENVELA

Impax Laboratories, Inc. today confirms that it has initiated a challenge of a patent listed by Genzyme Corporation in connection with RENVELA® (sevelamer carbonate for suspension), 2.4 g and 0.8 g.

3 Jul 2010

WHO Fracture Risk Assessment Tool version 3.1 launched

The WHO Fracture Risk Assessment Tool (FRAX-) has today been launched in version 3.1., featuring eight new country models and accessible in six additional languages.

3 Jul 2010

Strativa receives FDA approval for Zuplenz oral soluble film

Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Zuplenz® (ondansetron) oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting. Zuplenz, a unique formulation of ondansetron, is the first oral soluble film approved by the FDA as a prescription medication.

3 Jul 2010

Watson Laboratories receives FDA approval for Tacrolimus ANDA

Watson Pharmaceuticals, Inc., today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Tacrolimus 5 mg capsules, the generic equivalent to Astellas' Prograf® capsules.

2 Jul 2010

Studies demonstrate analgesic properties of synthetic cannabinoid

A new compound similar to the active component of marijuana (cannabis) might provide effective pain relief without the mental and physical side effects of cannabis, according to a study in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

2 Jul 2010

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Bristol-Myers Squibb Company and AstraZeneca today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improvement (as measured by glycosylated hemoglobin level (HbA1c)) in treatment-naive adults with type 2 diabetes mellitus inadequately controlled on diet and exercise compared to treatment with an investigational 10 mg dose of saxagliptin or metformin alone.

2 Jul 2010

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.

2 Jul 2010

Sensor-augmented insulin-pump therapy effective for type 1 diabetes patients

Adding a continuous blood sugar level sensor to an insulin pump helps patients with type 1 diabetes achieve better blood sugar control compared to the common standard of care, multiple daily insulin injections, concludes a study published on-line today in the New England Journal of Medicine.

2 Jul 2010

Twelve type 2 diabetes susceptibility loci identified

An international team co-led by scientists from the University of Michigan have discovered 12 more regions on the genome with DNA variants that are associated with increased risk of type 2 diabetes, bringing the number to 38.

2 Jul 2010

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Chelsea Therapeutics International, Ltd. announced the completion and favorable outcome of an independent Data Monitoring Committee (DMC) review of the safety and efficacy data from approximately half the target enrollment in Chelsea's Phase II trial of droxidopa in fibromyalgia.

2 Jul 2010

Visually impaired people dose accurately with insulin pens: Study

Labels on the popular insulin pen used by people with diabetes warn against visually-impaired people using pens to measure out and administer their insulin dosage.

2 Jul 2010

ISHLT issues first international consensus formulation of standardized nomenclature for CAV

Cardiac allograft vasculopathy (CAV), the major limitation to long term survival after heart transplantation, occurs when blood vessels in a transplanted heart progressively narrow and lead to dysfunction of the heart muscle or sudden death. Ascertaining benefit from appropriate treatment for this condition has been hampered in part because of the lack of a standard nomenclature.

2 Jul 2010

QR Pharma to present clinical data from mechanism of action study in MCI patients at ICAD 2010

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), announced today that it has been accepted to present a poster on clinical data from its recent mechanism of action study in mild cognitive impaired (MCI) patients at the International Congress on Alzheimer's Disease (ICAD 2010).

2 Jul 2010

Karolinska researchers recommend new routine for protection against infection during PEG

Researchers at Karolinska Institutet recommends a new routine for protection against infection when percutaneous endoscopic gastrostomy (PEG), a tube for feeding directly through the abdominal wall, is surgically inserted in the stomach. The new routine is both simpler and cheaper than the one used today. The method, presented in the British Medical Journal, has been clinically tested on over 200 patients at the Karolinska University Hospital in Solna, Stockholm County, Sweden.

2 Jul 2010

Compugen's CGEN-15001 recombinant fusion protein abolishes spontaneous relapses in animal model of MS

Compugen Ltd. announced today that administration of CGEN-15001 in an animal model of multiple sclerosis (MS) has been shown to completely abolish spontaneous relapses. In addition, administration of this novel molecule prior to disease onset demonstrated a pronounced delay of disease onset and a significant decrease in disease symptoms.

2 Jul 2010

Aushon BioSystems introduces new Human multiplex biomarker panels

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, has launched new Human multiplex biomarker panels for the quantification of eight biomarkers related to drug-induced kidney damage, or nephrotoxicity.

2 Jul 2010

Plant extract effective against ulcerative colitis in mice

A South Dakota State University scientist's research shows an extract made from a food plant in the Brassica family was effective in alleviating signs of ulcerative colitis, an inflammatory bowel condition, in mice.

2 Jul 2010

HL patients with heart disease at increased risk of hospitalization for cardiac complications after treatment

Older patients with Hodgkin lymphoma (HL) and a history of heart disease face a high risk of hospitalization for cardiac complications after completing treatment, according to research published online today in Blood, the journal of the American Society of Hematology. HL is a form of cancer of arising in the lymph nodes, and approximately 8,500 people were diagnosed with the disease in 2009, according to the American Cancer Society.

2 Jul 2010

Cambridge Heart announces CMS reimbursement modification for MTWA test

Cambridge Heart, Inc., today announced that effective July 1, 2010, the Centers for Medicare and Medicaid Services (CMS) will allow full reimbursement for both a Microvolt T-Wave Alternans (MTWA) test and a stress test when both tests are performed during the same patient visit. The CMS update removes a previous restriction that substantially limited reimbursement when a patient underwent an MTWA test on the same day as the patient underwent a standard cardiac stress test, echocardiography stress test, nuclear cardiac stress test, or pulmonary stress test.

2 Jul 2010

Parkinson's Disease Foundation awards $1.2M for research programs

The Parkinson's Disease Foundation (PDF) is pleased to announce awards totaling $1.2 million for research projects designed to understand the cause(s) of and find a cure for Parkinson's disease (PD).

2 Jul 2010

Medical Condition News

Impax confirms challenge of patent relating to RENVELA

WHO Fracture Risk Assessment Tool version 3.1 launched

Strativa receives FDA approval for Zuplenz oral soluble film

Watson Laboratories receives FDA approval for Tacrolimus ANDA

Studies demonstrate analgesic properties of synthetic cannabinoid

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Sensor-augmented insulin-pump therapy effective for type 1 diabetes patients

Twelve type 2 diabetes susceptibility loci identified

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Visually impaired people dose accurately with insulin pens: Study

ISHLT issues first international consensus formulation of standardized nomenclature for CAV

QR Pharma to present clinical data from mechanism of action study in MCI patients at ICAD 2010

Karolinska researchers recommend new routine for protection against infection during PEG

Compugen's CGEN-15001 recombinant fusion protein abolishes spontaneous relapses in animal model of MS

Aushon BioSystems introduces new Human multiplex biomarker panels

Plant extract effective against ulcerative colitis in mice

HL patients with heart disease at increased risk of hospitalization for cardiac complications after treatment

Cambridge Heart announces CMS reimbursement modification for MTWA test

Parkinson's Disease Foundation awards $1.2M for research programs

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News